The first anti-VEGF drug , a monoclonal antibody named bevacizumab , was approved in 2004 .
Hence , VEGF is a potential target for the treatment of cancer .
The first target drug , a monoclonal antibody named bevacizumab , was approved in 2004 .
Hence , VEGF is a potential target for the treatment of cancer .